Literature DB >> 22120020

A subset of chronic lymphocytic leukemia patients display reduced levels of PARP1 expression coupled with a defective irradiation-induced apoptosis.

Maria Giulia Bacalini1, Simona Tavolaro, Nadia Peragine, Marilisa Marinelli, Simona Santangelo, Ilaria Del Giudice, Francesca Romana Mauro, Valeria Di Maio, Maria Rosaria Ricciardi, Paola Caiafa, Sabina Chiaretti, Robin Foà, Anna Guarini, Anna Reale.   

Abstract

Chronic lymphocytic leukemia (CLL) is a heterogeneous disease characterized by defects in the DNA damage response and apoptosis. Among the factors involved in these pathways, we focused on the enzyme poly(ADP-ribose) polymerase 1 (PARP1) and on its substrate Che-1 by evaluating their basal expression and functional changes upon irradiation (IR). Microarray experiments were performed on 98 untreated CLL cases. Next, freshly isolated primary cells from 21 untreated patients were analyzed for in vitro response to irradiation through Western blot, PARP activity assay, Annexin-V analysis, and PARP1 basal expression by quantitative polymerase chain reaction. Microarray analysis showed that PARP1 and CHE1 were constitutively expressed in CLL and had a high degree of correlation with each other and with TP53. PARP1 and TP53 downmodulation was associated with worse clinical outcomes, especially in TP53-mutated cases. Next, CLL samples from 21 untreated patients were classified as responders and nonresponders based on IR-induced PARP1 cleavage. Notably, while responder samples were characterized by Che-1 and p53 induction at 8 hours and reduction at 24 hours post-IR, nonresponders included both samples with p53 dysfunctions and cases with a normal IR-induced Che-1 and/or p53 response. Finally, we observed that PARP1 was downregulated in nonresponder vs responder samples and that its basal expression was positively correlated with PARP1 cleavage after IR. In conclusion, we showed that reduced expression of PARP1 is associated with an impairment of CLL responsiveness to cell death. Copyright Â
© 2012 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22120020     DOI: 10.1016/j.exphem.2011.11.005

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  10 in total

1.  Che-1 is targeted by c-Myc to sustain proliferation in pre-B-cell acute lymphoblastic leukemia.

Authors:  Valentina Folgiero; Cristina Sorino; Matteo Pallocca; Francesca De Nicola; Frauke Goeman; Valentina Bertaina; Luisa Strocchio; Paolo Romania; Angela Pitisci; Simona Iezzi; Valeria Catena; Tiziana Bruno; Georgios Strimpakos; Claudio Passananti; Elisabetta Mattei; Giovanni Blandino; Franco Locatelli; Maurizio Fanciulli
Journal:  EMBO Rep       Date:  2018-01-24       Impact factor: 8.807

2.  AATF suppresses apoptosis, promotes proliferation and is critical for Kras-driven lung cancer.

Authors:  Daniela Welcker; Manaswita Jain; Safiya Khurshid; Mladen Jokić; Martin Höhne; Anna Schmitt; Peter Frommolt; Carien M Niessen; Judith Spiro; Thorsten Persigehl; Maike Wittersheim; Reinhard Büttner; Maurizio Fanciulli; Bernhard Schermer; Hans Christian Reinhardt; Thomas Benzing; Katja Höpker
Journal:  Oncogene       Date:  2018-01-11       Impact factor: 9.867

3.  Repair of endogenous DNA base lesions modulate lifespan in mice.

Authors:  Lisiane B Meira; Jennifer A Calvo; Dharini Shah; Joanna Klapacz; Catherine A Moroski-Erkul; Roderick T Bronson; Leona D Samson
Journal:  DNA Repair (Amst)       Date:  2014-06-30

Review 4.  Che-1/AATF: A Critical Cofactor for Both Wild-Type- and Mutant-p53 Proteins.

Authors:  Tiziana Bruno; Simona Iezzi; Maurizio Fanciulli
Journal:  Front Oncol       Date:  2016-02-15       Impact factor: 6.244

5.  Serum and antibodies of glaucoma patients lead to changes in the proteome, especially cell regulatory proteins, in retinal cells.

Authors:  Katharina Bell; Sebastian Funke; Norbert Pfeiffer; Franz H Grus
Journal:  PLoS One       Date:  2012-10-11       Impact factor: 3.240

6.  Aag DNA glycosylase promotes alkylation-induced tissue damage mediated by Parp1.

Authors:  Jennifer A Calvo; Catherine A Moroski-Erkul; Annabelle Lake; Lindsey W Eichinger; Dharini Shah; Iny Jhun; Prajit Limsirichai; Roderick T Bronson; David C Christiani; Lisiane B Meira; Leona D Samson
Journal:  PLoS Genet       Date:  2013-04-04       Impact factor: 5.917

Review 7.  Discovering Che-1/AATF: a new attractive target for cancer therapy.

Authors:  Simona Iezzi; Maurizio Fanciulli
Journal:  Front Genet       Date:  2015-04-10       Impact factor: 4.599

8.  PARP1-driven apoptosis in chronic lymphocytic leukemia.

Authors:  Panagiotis T Diamantopoulos; Maria Sofotasiou; Vasiliki Papadopoulou; Katerina Polonyfi; Theodoros Iliakis; Nora-Athina Viniou
Journal:  Biomed Res Int       Date:  2014-08-03       Impact factor: 3.411

9.  PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia.

Authors:  Ashleigh Herriott; Susan J Tudhope; Gesa Junge; Natalie Rodrigues; Miranda J Patterson; Laura Woodhouse; John Lunec; Jill E Hunter; Evan A Mulligan; Michael Cole; Lisa M Allinson; Jonathan P Wallis; Scott Marshall; Evelyn Wang; Nicola J Curtin; Elaine Willmore
Journal:  Oncotarget       Date:  2015-12-22

10.  CK2-mediated phosphorylation of Che-1/AATF is required for its pro-proliferative activity.

Authors:  Valeria Catena; Tiziana Bruno; Simona Iezzi; Silvia Matteoni; Annalisa Salis; Cristina Sorino; Gianluca Damonte; Maurizio Fanciulli
Journal:  J Exp Clin Cancer Res       Date:  2021-07-15
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.